Clinical Trial

Edaravone in the Treatment of Optic Neuritis

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-09-11; most recent amendment 2025-02-25.
Trial Details
NCT Number NCT05540262
Lead Sponsor First Affiliated Hospital of Guangxi Medical University
Conditions Optic Neuritis
Enrollment 50 participants
Start Date 2022-01-15
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-27